Jun
11
Forbes Reports on HGH Drug Companies
June 11, 2009 | Leave a Comment
 Two prominate drug companies decide to end thier HGH making deal, according to Forbes:
After partnering up only a year ago, investors and analysts were confused as to why Genentech chose to end its collaboration with Altus to jointly create HGH.
Altus (nasdaq: ALTU - news - people ) announced late Wednesday that it regained the rights from Genentech (nyse: DNA - news - people ) to develop and market the drug known as ALTU-238 in North America. According to Altus, Genentech declined an option to sell the drug internationally.
ALTU-238 is an experimental treatment intended for patients who lack the proper amount of the HGH. The drug, taken weekly, is a version of that hormone.
Dec
21
Forbes Reports on HGH Drug Companies
December 21, 2007 | Leave a Comment
 Two prominate drug companies decide to end their HGH partnership, according to Forbes:
After partnering up only a year ago, investors and analysts were confused as to why Genentech chose to end its collaboration with Altus to jointly create HGH.
Altus announced late Wednesday that it regained the rights from Genentech to develop and market the drug known as ALTU-238 in North America. According to Altus, Genentech declined an option to sell the drug internationally.
ALTU-238 is an experimental treatment intended for patients who lack the proper amount of the HGH. The drug, taken weekly, is a version of that hormone.
Recommended Links
GET YOUR FREE HGH &
ANTI-AGING REPORT!
- Get your own FREE copy of the groundbreaking report, "Seven Age Reversing Secrets" – packed with valuable tips and tricks to help you fight the aging process and have the highest quality of life possible!